[go: up one dir, main page]

MX2008001706A - Conjugados de una porcion g-csf y un polimero. - Google Patents

Conjugados de una porcion g-csf y un polimero.

Info

Publication number
MX2008001706A
MX2008001706A MX2008001706A MX2008001706A MX2008001706A MX 2008001706 A MX2008001706 A MX 2008001706A MX 2008001706 A MX2008001706 A MX 2008001706A MX 2008001706 A MX2008001706 A MX 2008001706A MX 2008001706 A MX2008001706 A MX 2008001706A
Authority
MX
Mexico
Prior art keywords
conjugates
polymer
csf moiety
methods
compositions
Prior art date
Application number
MX2008001706A
Other languages
English (en)
Inventor
Mary J Bossard
Ping Zhang
Original Assignee
Nektar Therapeutics Al Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics Al Corp filed Critical Nektar Therapeutics Al Corp
Publication of MX2008001706A publication Critical patent/MX2008001706A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • C08G73/10—Polyimides; Polyester-imides; Polyamide-imides; Polyamide acids or similar polyimide precursors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los conjugados de una porcion G-CSF y uno o mas polimeros solubles en agua no peptidicos se proporcionan. Tipicamente, el polimero soluble en agua no peptidico es poli(etilen glicol) o un derivado del mismo. Tambien se proporciona, entre otras cosas, composiciones que comprenden conjugados, metodos para hacer conjugados, y metodos para administrar composiciones que comprenden conjugados a un paciente.
MX2008001706A 2005-08-04 2006-08-04 Conjugados de una porcion g-csf y un polimero. MX2008001706A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70596805P 2005-08-04 2005-08-04
US75282505P 2005-12-21 2005-12-21
PCT/US2006/030481 WO2007019331A2 (en) 2005-08-04 2006-08-04 Conjugates of a g-csf moiety and a polymer

Publications (1)

Publication Number Publication Date
MX2008001706A true MX2008001706A (es) 2008-04-07

Family

ID=37621974

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008001706A MX2008001706A (es) 2005-08-04 2006-08-04 Conjugados de una porcion g-csf y un polimero.

Country Status (11)

Country Link
US (1) US20070092482A1 (es)
EP (1) EP2099495A2 (es)
JP (1) JP2009503111A (es)
KR (1) KR20080033439A (es)
CN (1) CN101257926A (es)
AU (1) AU2006278490A1 (es)
BR (1) BRPI0614257A2 (es)
CA (1) CA2617064A1 (es)
IL (1) IL188999A0 (es)
MX (1) MX2008001706A (es)
WO (1) WO2007019331A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE494012T1 (de) † 2004-12-21 2011-01-15 Nektar Therapeutics Stabilisierte polymer-thiol-reagenzien
EP1861125A2 (en) * 2005-03-23 2007-12-05 Nektar Therapeutics Al, Corporation Conjugates of an hgh moiety and peg derivatives
WO2006138572A2 (en) 2005-06-16 2006-12-28 Nektar Therapeutics Al, Corporation Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
KR20090046923A (ko) 2006-08-04 2009-05-11 프로롱 파마슈티컬스, 인크. 수식된 에리스로포이에틴
BRPI0720619B1 (pt) 2006-12-27 2022-04-05 Nektar Therapeutics Composto de fator ix-poli(etileno glicol) com uma ligação liberável, método para preparar o mesmo e composição
AU2007340382B2 (en) 2006-12-27 2013-06-27 Nektar Therapeutics Von Willebrand Factor- and Factor VIII-polymer conjugates having a releasable linkage
TW200922624A (en) * 2007-07-11 2009-06-01 Enzon Pharmaceuticals Inc Polymeric drug delivery system containing a multi-substituted aromatic moiety
BRPI0722341A2 (pt) * 2007-12-29 2014-03-18 Biosteed Gene Expression Tech Co Ltd G-csf modificado por polietileno glicol em forma de y, a preparação e uso do mesmo
US8629104B2 (en) 2008-02-18 2014-01-14 Jiangsu Hengrui Medicine Co. Ltd. G-CSF and water-soluble polymer conjugate
WO2010014258A2 (en) 2008-08-01 2010-02-04 Nektar Therapeutics Al, Corporation Conjugates having a releasable linkage
EP2331569A1 (en) 2008-08-21 2011-06-15 Octapharma AG Recombinantly produced human factor viii and ix
CN101870728A (zh) 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 新型Exendin变体及其缀合物
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
US20120191039A1 (en) * 2009-07-31 2012-07-26 Ascendis Pharma A/S Carrier linked pramipexole prodrugs
TW201138831A (en) * 2009-09-30 2011-11-16 Prolong Pharmaceuticals Inc Modified granulocyte colony stimulating factor (G-CSF)
BR112012027055B1 (pt) * 2010-04-20 2019-09-17 Octapharma Ag Método para estabilizar uma proteína do plasma de sangue humano, composição, e uso da melezitose
WO2012064867A1 (en) * 2010-11-09 2012-05-18 Nektar Therapeutics Pharmacologically active polymer-g-csf conjugates
WO2012064845A2 (en) * 2010-11-09 2012-05-18 Nektar Therapeutics G-csf polymer conjugates having a releasable linkage
RS61854B1 (sr) * 2010-11-12 2021-06-30 Nektar Therapeutics Konjugati il-2 dela i polimera
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HRP20181300T1 (hr) 2012-12-21 2018-10-05 Sanofi Derivati eksendina-4 kao dvostruki glp1/gip- ili trostruki glp1/gip/glukagon agonisti
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
JP2016144812A (ja) * 2015-02-06 2016-08-12 富士通株式会社 フラックス及び電子装置の製造方法
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016201448A2 (en) * 2015-06-11 2016-12-15 Prolong Pharmaceuticals, LLC Pegylated granulocyte colony stimulating factor (gcsf)
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
US20250269045A1 (en) * 2024-02-22 2025-08-28 Pharmaessentia Corporation Unique pegylated granulocyte colony stimulating factor, methods of use and preparation thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US5618697A (en) * 1982-12-10 1997-04-08 Novo Nordisk A/S Process for preparing a desired protein
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US6004548A (en) * 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5362853A (en) * 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
JP2958019B2 (ja) * 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
US5214131A (en) * 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US20020177688A1 (en) * 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
AU1462392A (en) * 1991-02-22 1992-09-15 Amgen, Inc. Use of gm-csf and g-csf to promote accelerated wound healing
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
ES2224649T3 (es) * 1998-04-28 2005-03-01 Applied Research Systems Ars Holding N.V. Conjugados de poliol-ifn-beta.
CN1376164A (zh) * 1999-01-29 2002-10-23 霍夫曼-拉罗奇有限公司 Gcsf缀合物
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
EP1317537B1 (en) * 2000-09-08 2006-12-20 Massachusetts Institute Of Technology G-csf analog compositions and methods
US7053150B2 (en) * 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
EP1490402A4 (en) * 2002-03-20 2007-05-02 Biopolymed Inc PREPARATION OF CYSTEINREST STOCHIOMETRIC WITH BIOKOMPATIBLE POLYMER CONJUGATED G-CSF
WO2004075923A2 (en) * 2003-02-26 2004-09-10 Nektar Therapeutics Al, Corporation Polymer-factor viii moiety conjugates
US20040180054A1 (en) * 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
ATE494012T1 (de) * 2004-12-21 2011-01-15 Nektar Therapeutics Stabilisierte polymer-thiol-reagenzien

Also Published As

Publication number Publication date
JP2009503111A (ja) 2009-01-29
WO2007019331A2 (en) 2007-02-15
IL188999A0 (en) 2008-08-07
WO2007019331A3 (en) 2007-11-08
AU2006278490A1 (en) 2007-02-15
KR20080033439A (ko) 2008-04-16
CA2617064A1 (en) 2007-02-15
CN101257926A (zh) 2008-09-03
BRPI0614257A2 (pt) 2011-03-15
US20070092482A1 (en) 2007-04-26
EP2099495A2 (en) 2009-09-16

Similar Documents

Publication Publication Date Title
MX2008001706A (es) Conjugados de una porcion g-csf y un polimero.
WO2006005058A3 (en) Polymer-factor ix moiety conjugates
WO2004075923A3 (en) Polymer-factor viii moiety conjugates
MXPA05003394A (es) Conjugados de polimero con antigenicidad disminuida, metodos de preparacion y usos de estos.
EP2279758A3 (en) Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
WO2006110776A3 (en) Polyethylene glycol cojugates of antimicrobial agents
MX2013005363A (es) Conjugados de un resto de interleucina-2 y un polimero.
NZ538624A (en) Water-soluble polymer alkanals
WO2011062965A8 (en) Targeting monomers and polymers having targeting blocks
WO2015153753A3 (en) Conjugates of an il-15 moiety and a polymer
JO2932B1 (en) Lyspro insulin compounds linked to PEG
WO2006012527A8 (en) Bivalent linkers and conjugates thereof
WO2007100905A3 (en) Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
WO2009139905A3 (en) Conjugates of a cholinesterase moiety and a polymer
ATE246202T1 (de) Gcsf konjugate
WO2005089805A3 (en) Polymer-based compositions and conjugates of hiv entry inhibitors
WO2006138463A3 (en) Polymer-based compositions and conjugates of non-steroidal anti-inflammatory drugs
WO2006019950A3 (en) Conjugates of a gm-csf moiety and a polymer
TW200635576A (en) Releasable polymeric conjugates based on aliphatic biodegradable linkers
GB2426703B (en) Compositions
CA2726043A1 (en) Oral care composition comprising an adhesive component
WO2007117685A3 (en) Conjugates of an anti-tnf-alpha antibody
WO2005084303A3 (en) Interferon-beta polymer conjugates
WO2008011165A3 (en) Polymeric reagents comprising a terminal vinylic group and conjugates formed therefrom
WO2006089228A3 (en) Conjugates of an epo moiety and a polymer

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: NEKTAR THERAPEUTICS